Text Size

Anti-Aggregative Therapy and Laser Iridectomy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Sheba Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00426400
First received: October 25, 2006
Last updated: January 23, 2007
Last verified: January 2007
History of Changes
  Purpose

Our study investigates the effect of anti-aggregative treatment on success and complications of laser iridectomy. The study includes patients scheduled for laser iridectomy due to narrow angles.Patients will undergo first laser treatment with the anti-aggregative treatment and will scheduled for next lase in the other eye after discontinuing the anti-aggregative treatment. The patients will be followed-up for 3 months.


Condition Intervention Phase
Eyes With Narrow Angle
 Drug: The cessation of anti-aggregative treatment for 10 days
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Sheba Medical Center:

Study Start Date: March 2006
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with narrow angle that need laser iridectomy and take anti- aggregative treatment
  • over 20 years old
  • patients who can stop their anti-aggregative treatment for 10 days

Exclusion Criteria:

  • under coumadin treatment
  • post ocular surgeries
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00426400

Contacts
Contact: Hani Levkovitch-Verbin, MD Hani.Verbin@ sheba.health.gov.il

Locations
Israel
Goldschleger Eye Institute Recruiting
Tel-Hashomer, Israel
Contact: Hani Levkovitch-Verbin, MD         halevko@hotmail.com    
Principal Investigator: Hani Levkovitch-Verbin, MD            
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Hani Levkovitch-Verbin, MD Goldscheleger Eye Institute, Sheba Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00426400     History of Changes
Other Study ID Numbers: SHEBA-05-3876-HLV-CTIL
Study First Received: October 25, 2006
Last Updated: January 23, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

ClinicalTrials.gov processed this record on May 22, 2013